deltatrials
Completed PHASE1/PHASE2 NCT00990639

Effect of Candesartan in Alcoholic Liver Fibrosis

Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial

Sponsor: Yonsei University

Conditions Alcoholic Liver Disease
Interventions candesartan for hepatic fibrosis
Updated 5 times since 2017 Last updated: Oct 6, 2009 Started: Sep 30, 2005 Primary completion: Dec 31, 2008 Completion: Mar 31, 2009

This PHASE1/PHASE2 trial investigates Alcoholic Liver Disease and is currently completed. Yonsei University leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Yonsei University
Data source: Yonsei University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Wŏnju, South Korea